Persistent olmesartan-based blood pressure–lowering effects on morning hypertension in Asians: the HONEST study

Abstract

Using data from the large-scale HONEST (Home blood pressure measurement with Olmesartan Naive patients to Establish Standard Target blood pressure) study, we investigated the characteristics of the effects of olmesartan-based treatment on morning hypertension in Asian hypertensive patients. Specifically, we investigated the relationship between baseline blood pressure (BP) and BP reduction after 16 weeks by linear regression analyses; determinants of BP reduction were also investigated. For both morning home BP (MHBP) and clinic BP (CBP), reduced systolic BP (SBP) after 16 weeks was associated with baseline SBP (P<0.001). The slope of the regression lines was similar for morning home SBP (MHSBP) (−0.744) and clinic SBP (−0.735). Although sex, concomitant diabetes mellitus and concomitant hepatic disease significantly influence the relationship between BP reduction and baseline BP for MHSBP, none were deemed clinically relevant. In conclusion, olmesartan-based treatment robustly reduced baseline high MHBP, similar to CBP, and the effect was associated with baseline BP but unaffected by patient background factors.

Home sphygmomanometers can help in the control of blood pressure: a nationwide field survey

“…Home blood pressure monitoring (HBPM) integrates patients into their treatment program and is a common selfmanagement tool, especially in developed countries [1][2][3][4][5]. Substantial evidence regarding the usefulness of HBPM in the management of hypertension (HT) has accumulated over the last two decades [6][7][8][9], and HBPM is recommended in HT guidelines [10][11][12][13][14]. Home blood pressure (BP) monitoring can also be supported by pharmacy assistance, telemonitoring or self-management programs [15][16][17].…”